Logo image
Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors
Journal article   Open access   Peer reviewed

Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors

Staci L Haney, Veronica S Wills, David F Wiemer and Sarah A Holstein
Molecules (Basel, Switzerland), Vol.22(6), p.886
05/27/2017
DOI: 10.3390/molecules22060886
PMCID: PMC5902023
PMID: 28555000
url
https://doi.org/10.3390/molecules22060886View
Published (Version of record) Open Access

Abstract

The enzyme geranylgeranyl diphosphate synthase (GGDPS) catalyzes the synthesis of the 20-carbon isoprenoid geranylgeranyl diphosphate (GGPP). GGPP is the isoprenoid donor for protein geranylgeranylation reactions catalyzed by the enzymes geranylgeranyl transferase (GGTase) I and II. Inhibitors of GGDPS result in diminution of protein geranylgeranylation through depletion of cellular GGPP levels, and there has been interest in GGDPS inhibitors as potential anti-cancer agents. Here we discuss recent advances in the development of GGDPS inhibitors, including insights gained by structure-function relationships, and review the preclinical data that support the continued development of this novel class of drugs.
Terpenes - pharmacology Farnesyltranstransferase - metabolism Protein Prenylation - drug effects Terpenes - chemistry Animals Enzyme Inhibitors - chemistry Humans Enzyme Inhibitors - pharmacology Farnesyltranstransferase - antagonists & inhibitors Structure-Activity Relationship

Details

Metrics

Logo image